๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Turn Therapeutics Inc. (TTRX)
NASDAQ: TTRX ยท Real-Time Price ยท USD
8.89
+0.34 (3.98%)
Nov 18, 2026, 4:00 PM EST - Market closed
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

Phase IIb eczema development uses itch-score enrichment and is expected to read out in Q1 2027; the first 50 patients showed endpoint separation in the high-itch subgroup. Onychomycosis and hidradenitis suppurativa programs are advancing, with runway through end-2027.

Brad Burnam
Founder and CEO, Turn Therapeutics

Appreciate the attendance. Appreciate everybody joining. Sorry about the delay, and I know that there have been a number of travel disruptions this week, so I appreciate Jefferies giving me the opportunity to present virtually. My name is Brad Burnam, founder and CEO of Turn Therapeutics. I am also the creator of the technology that we will be discussing today, so I know it quite intimately. Today, we are going to be discussing not just the company, but the programs that we are working on as well. The origin story of Turn is a bit unusual, but it is something that encompassed a large period of my life. I actually immediately spent about 10 years in sales, in medical device sales after graduate school.

I worked in initially neuromodulation, then I went into the pacemaker defibrillator side of things and spent a lot of time in the hospitals, a lot of interaction with patients, a lot of time in the operating room. It also gave me a really strong familiarity with what it is like to actually be a medical rep in the field, which gives me a unique commercial perspective when I am developing products and looking at their pros and cons per se. Because of interacting with patients, you also are susceptible to organisms, and contagious diseases, and such things. I actually picked up a hospital-acquired infection in December of 2009 through work, which led me to have about three years of chronic wounds.

I spent six months at a time, six days a week in advanced wound care clinics, getting chronically infected wounds packed, and it gave me a very strong familiarity with what was being used in the wound care space, which is where Turn began. It also gave me a bit of a frustration with the products that were in use in that space, products like Neosporin and honey and silver-based products that I felt were not necessarily up to the level of technology we were seeing in the therapeutic side. So, it became a goal for me to create a better wound care product, not just for everybody to use, but initially for me to use. I wanted to get my wounds to close. I found an API called polyhexanide in Europe that had been used extensively in European countries as a wound flush, as an antimicrobial, as an anti-inflammatory.

As a liquid API, it was not necessarily suitable for a viscous ointment, which is what I was hoping to make for a wound care product in the U.S. But I was able to formulate it inside of an oil carrier using a process that we call PermaFusion now, which is permanently suspending a polar water-soluble ingredient inside of an oil carrier without an emulsifier. Very unique properties. It allows us to use less of the API while still actually having the same bioavailability as if it were more. Using that process, I created GX-03, which is sort of our flagship formula still to this day. It has an interesting novel MOA. It has IL-36 reduction, IL-31 reduction. We will talk about that later. It also has effects on microbes such as bacteria, fungus, and yeast.

I was able to actually get FDA clearance for this formula, initially in the beginning, just sort of on my own with some seed funding at the end of 2016. Then we got two more actually in the wound care space in 2017 and 2019. Over the course of this product being out there, initially as a wound care product, we saw use in over 200,000 people, and we saw a lot of other use profiles that doctors were using it for. Most consistently, we saw it in eczema and in tinea fungus. These were not things that I was initially thinking about in the wound care space, but therapeutic use cases that were becoming more and more prominent that we were seeing reports and publications about. I sought some help.

You will see we have a pretty amazing team of board members, advisors, and team members, because in this therapeutic side, I needed guidance. They told me to essentially bifurcate the company, treat the wound care side as a consistent, potentially passive revenue generator using some of the assets that obtained clearance, then focus on the therapeutic development of the main formula, GX-03. I wanted to really understand why it was helping people in eczema, why these reports were coming in that the itching was going away, that the skin was healing so well. I understood on the wound care side that it could actually help heal the skin, but why were they reporting that they were having reduced symptoms in terms of such things as itching and quality of life?

I had a working theory that we were affecting the initial cytokine release in the inflammatory skin cascade, or IL-36. IL-36 is actually the only in vivo measurement for whether or not the epithelium is under duress. If you cut your skin, if it is cold and it cracks, if there is an inflammatory insult to the skin, if there is a pathogenic insult, the skin first releases IL-36, which leads to the downstream effects we know of, such as TH2, IL-31. You see your 4s and your 13s under the TH2 area. People are very familiar with those.

I had a theory that we were actually blunting that initial response and therefore reducing the downstream effects of the additional cytokines, and we proved this over two publications that we put out this past year, that we inhibited IL-36 and a very large amount of IL-31 as well, which is the quality of life, neuroeffective cytokine that affects itching. From this point, we knew that we had a strong safety profile, given its history in the wound care space, an interesting mechanism of action theory that we were able to put out in those publications. We wanted to try this drug in humans, specifically for atopic dermatitis. Now, going into a phase IIa, we needed to enable it obviously with an endpoint, but we really wanted to treat this first stage. You can call it stage 1, stage 2.

I prefer to think of it as a phase II-A, a phase II-B. It's up to people how they want to refer to it. But we took this first 50 patients. We used a very wide inclusion criteria. You just needed to have an IGA of at least three or an EASI of at least seven to be included in the trial. And we wanted to look at it at the end of the 50 patients using an IDMC and then optimize stage 2 based upon what we saw. And we really looked at these four main efficacy endpoints as targets. Week 4 IGA is something people are very familiar with. A lot of products have this as a registrational endpoint, like Pfizer's drug, for example. EASI targets are not as common in topicals. We typically see them focusing solely on IGA. This tends to be more biologics.

But we saw some interesting separation in the ITT group. When you're building a trial out for the optimized stages, you want to look toward enrichment targets. What's an enrichment target? It's how you can sort of focus on one endpoint or another, focus on one criteria or another to actually show the drug signal the best. Most systemic drugs, and frankly, a lot of even topical drugs, really look at patients with a higher EASI. We noticed that we had effectiveness across the whole EASI spectrum, 1.1 and up. And we didn't necessarily want to limit ourselves to that. We wanted to keep our patients in the IGA of three or four, the moderate to severe lesion, but we wanted to make sure that we had the entire EASI spectrum covered. So, we found another interesting potentially candidate biomarker in pruritus.

So pruritus is obviously the itch score, PP-NRS. If you see that as we went up in the self-reported itch, see PP-NRS of five, which is just that midpoint of zero to 10, 40 of the patients had at least that. We saw actually statistically significant separation in the week 4 IGA. It's 40 people, 80% of the trial. As we went up to six, 35 patients, we saw an even greater separation. As we hit the seven mark, we saw sort of a broader separation across multiple endpoints, including 46.2% versus 8.3% at EASI-100 week eight, which is an incredible potential endpoint to be pursuing.

And we decided that for stage 2 of the trial, even though we plan on including five and six in our phase III program, for the sake of efficiency, we're going to use PP-NRS as an enrichment target while keeping the full EASI spectrum. So, the current stage 2 or phase II-B of our adaptive trial looks a bit like this, which I'll put into English, of course. We have all 3 EASI buckets, stratum, the fancy term is, of course, but it's the different sides of the spectrum. We've got our lower EASI quartile, 1.1 to 7. You can think of that as the patients with maybe just severe hand eczema or severe face eczema. Then our moderate coverage, 7.1 to 15.9. And then, of course, our EASI of greater than or equal to 16, which is where we see our systemic drugs usually targeted.

We're enriching for PP-NRS of seven, as we mentioned. Anybody with an EASI of 1.1 or up is eligible, and it's a BID topical eight-week trial. If we took this criteria and we overlaid it back on the first 50 people, you see an EASI curve that is very encouraging. You see a pretty large separation at the week four mark. The fast and safe target is what we're really targeting. Continued separation into week eight. Of course, you're going to get some compression considering our placebo is an ointment. If you look at this chart, this table of what our phase IIa would have looked like with the exact design of our phase IIb, we see a week 4 IGA success with a 0.01 p-value. It was a wonderful surprise that we got this incredible level of separation once we put this back in there.

Looking down the list, week four EASI 75. We have to remember that EASI 75, EASI 90, EASI 100 are not typical topical targets. Typically, we're really just looking at IGA. It's pretty amazing to see some separation into where we're used to seeing the systemic injectables. Again, the drum that I beat all the time is safe, fast, and safe. That is the commercial premise that we're pursuing. We only had one patient with a mild warming sensation on the drug side. Another on the placebo side reported a common cold. That was across all 50 patients for eight weeks at at least two time-of-day application. As we know, this is a very large market with varied treatment options.

Usually, the people in the less than 14 to 16 EASI are left with topicals, things like steroids and Vtama and OPZELURA, because their insurance doesn't qualify them for the systemics because their EASI coverage of their body is not as high. We think that those people should have options other than those, and that's a very large opportunity for us in this space and also for the patients. We don't necessarily think that we would replace biologics. I think it would be kind of loony for a CEO to say that. There is no reason for a product that can't help bridge to those biologics that is non-systemic, doesn't have a large side effect profile, and can get those people feeling better while they're bridging onto their biologics. So, another indication that we saw a great deal of use in is onychomycosis, or toenail fungus.

This was an interesting story because the President of the American Podiatric Medical Association actually published an investigator-initiated trial using the wound care formula, the GX-03 that I mentioned, which is the same formula in trials for eczema, and he got a 70%-85% complete cure on infected toenails, which is very high compared to current topicals on the market. You see the range from 6.5% to 17.8% in their phase III trials. In vivo, we were curious as to why it was working as well as it was. We inoculated toenails, and we were able to prove that it does in fact penetrate the toenail and eliminate them inside of the inoculated surface, which a lot of these products have trouble doing. This particular product has a huge opportunity in the market.

When you have orals that people are used to taking, oral terbinafine topicals with this kind of a profile, there is obviously a huge commercial opportunity. It is a big market. Less than 30% of the people that have toenail fungus even go to the doctor because they do not think that there are a lot of good options for them. A safe topical with a potential use profile or safety and efficacy profile above the current systemic, which is in that 40%-50% efficacy, is a pretty amazing opportunity. This particular trial is actually a phase III, or this particular program is a phase III-ready program. It is financing dependent, but we have this design, we have met with the agency, and we are looking forward to beginning this sometime in 2027. Quickly before we close up, we are pursuing a phase IIa in hidradenitis suppurativa.

It has become a popular indication as of late. We think it is a very logical target for our profile. We know from published research and the studies that we have done that we affect the IL-36 pathway, which is associated with HS. We also know from our published claims that we have a strong effect on the microbes that perpetuate the HS abscesses. HS is a bit of a chicken or the egg. You have an inflammatory skin disease that is accelerated and exacerbated by microbes. If we affect the inflammatory portion as well as the microbial portion, we think we have a very logical topical for this space. This phase IIa, we are scheduled to enroll as soon as February. It is a 40 on 40 design for Hurley patients stage I and II.

We are actually using a Holm two-sided test because we want to be able to look at week eight and week 16. A lot of the drugs on the market look for week 12 or week 16. We are interested in seeing if there is an early effect as well as a later effect. A lot of different portions of this trial, we are making sure to design it with our incredible team, that I will talk about in a later slide, that we want to make sure that we are not being, I will call it hit as much by the natural disease variability you tend to see in other trials. We are very aware of it. Bit of the timeline. You can see that we are reading out our phase IIb for eczema in Q1 of 2027. We are expecting our HS trial to begin about halfway through Q1.

Onychomycosis, financing dependent, we are hoping to begin it toward the middle of 2027, latter half of 2027. Unusual company in the way we went public. We actually direct listed in October of 2025. Goodness, it has been a year. We have accomplished a lot in our first year, and we are very proud of it. But I built this company on a shoestring, and we still run it very lean. We have only burned $24 million since inception. We spend about $1 million a quarter. We have got runway through the end of 2027, extensive IP families, seven families with 17 issued patents, coverage of compositions and methods through 2040 as of right now.

I think probably my favorite slide in the whole deck is the people that have helped me get this company to where it is, at the cost that we've been able to do it, is because I have the most amazing team on Earth. Dr. Neil Ghodadra has been with me since the beginning. I've got Dr. Robert Redfield, former CDC director, working on our science, an immunology expert. Dr. Stephen Hahn, former FDA commissioner, who's designing our clinical programs and helping us with the regulatory pathway. Sasha Damouni, an IR heavyweight, as everybody knows. Then our board members like Arthur Golden from Davis Polk, and Andrew Gengos from Amgen at Turn, Kent Kester, head of R&D at CEPI, Martin Dewhurst, an incredible guy who spent 10 years as the global co-head of McKinsey Life Sciences. It's really just an amazing honor to work with these people.

I think we're in a really good place, and I'm looking forward to interacting with people in the room who may have questions and more and more with investors in follow-up meetings. Just want to thank you for your time.

Speaker 2

Thank you, Brad. Does anyone have any questions? No, I think we're all good then. Thank you, Brad. Okay.

Brad Burnam
Founder and CEO, Turn Therapeutics

Thank you very much for introducing, and I wish everybody a good day.

Speaker 2

Thank you.